{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"KeywordList": [["Crocus sativus", "Rhodiola rosea", "anxiety", "major depressive disorder"]], "SpaceFlightMission": [], "InvestigatorList": [], "OtherAbstract": [], "OtherID": [], "CitationSubset": [], "GeneralNote": [], "PMID": "30034237", "DateRevised": {"Year": "2022", "Month": "03", "Day": "18"}, "Article": {"ArticleDate": [{"Year": "2018", "Month": "07", "Day": "13"}], "Language": ["eng"], "ELocationID": ["10.2147/NDT.S169575"], "Journal": {"ISSN": "1176-6328", "JournalIssue": {"Volume": "14", "PubDate": {"Year": "2018"}}, "Title": "Neuropsychiatric disease and treatment", "ISOAbbreviation": "Neuropsychiatr Dis Treat"}, "ArticleTitle": "A preliminary assessment of a combination of rhodiola and saffron in the management of mild-moderate depression.", "Pagination": {"StartPage": "1821", "EndPage": "1829", "MedlinePgn": "1821-1829"}, "Abstract": {"AbstractText": ["The medicinal plants <i>Rhodiola rosea</i> L. (rhodiola, golden root) and <i>Crocus sativus</i> L. (saffron) have been shown separately to induce significant effects in depression. The objective of this study was to assess a fixed combination of rhodiola and saffron in mild-moderate depression.", "In this observational study conducted with general practitioners (GPs), 45 adults (aged 18-85 years) suffering from mild or moderate depression (International Statistical Classification of Diseases and Related Health Problems 10th Revision definition) and reaching a score on the Hamilton Rating Scale for Depression of 8-18 were supplemented with a combination of rhodiola and saffron extracts (one tablet, 154 mg of rhodiola and 15 mg of saffron; recommended dose two tablets per day for 6 weeks).", "After 6 weeks (D42) of supplementation, Hamilton Rating Scale for Depression scores (primary outcome) decreased significantly by 58%\u00b128.5% (from 13.6\u00b12.3 at D0 to 5.6\u00b13.8 at D42, <i>P</i><0.0001; n=41). Score improvement was reported in 85.4% of patients. A significant drop in both Hospital Anxiety and Depression Scale anxiety and depression scores was also observed at D42, the decrease being significant from 2 weeks of supplementation. At the end of the study, both GPs and patients deemed there was a significant improvement in depression (Clinical Global Impression - improvement and Patient Global Impression of Change). Safety was excellent, and no serious adverse effects were recorded.", "Results of this observational study performed in primary care suggest that the combination of rhodiola and saffron tested could be useful for the management of mild-moderate depression and improve depressive and anxiety symptoms. A double-blind placebo-controlled study is needed to confirm these results."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Groupe PiLeJe, Paris, France, c.blondeau@pileje.com."}], "LastName": "Bangratz", "ForeName": "Marie", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Groupe PiLeJe, Paris, France, c.blondeau@pileje.com."}], "LastName": "Ait Abdellah", "ForeName": "Samira", "Initials": "S"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Groupe PiLeJe, Paris, France, c.blondeau@pileje.com."}], "LastName": "Berlin", "ForeName": "Aur\u00e9lie", "Initials": "A"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Groupe PiLeJe, Paris, France, c.blondeau@pileje.com."}], "LastName": "Blondeau", "ForeName": "Claude", "Initials": "C"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Groupe PiLeJe, Paris, France, c.blondeau@pileje.com."}], "LastName": "Guilbot", "ForeName": "Ang\u00e8le", "Initials": "A"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Groupe PiLeJe, Paris, France, c.blondeau@pileje.com."}], "LastName": "Dubourdeaux", "ForeName": "Michel", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Clinique Lyon Lumi\u00e8re, Meyzieu, France."}], "LastName": "Lemoine", "ForeName": "Patrick", "Initials": "P"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "New Zealand", "MedlineTA": "Neuropsychiatr Dis Treat", "NlmUniqueID": "101240304", "ISSNLinking": "1176-6328"}, "CoiStatement": "Disclosure MB, SAA, AB, CB, AG, and MD are employees of Groupe PiLeJe. PL is a consultant for PiLeJe. The authors report no other conflicts of interest in this work."}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Hirschfeld RM. The epidemiology of depression and the evolution of treatment. J Clin Psychiatry. 2012;73(Suppl 1):5\u20139.", "ArticleIdList": ["22951236"]}, {"Citation": "Craven MA, Bland R. Depression in primary care: current and future challenges. Can J Psychiatry. 2013;58(8):442\u2013448.", "ArticleIdList": ["23972105"]}, {"Citation": "World Health Organization . Depression and Other Common Mental Disorders: Global Health Estimates. Geneva: WHO; 2017."}, {"Citation": "World Health Organization  D\u00e9pression. 2018.  [Accessed February 28, 2018].  Available from:  http://www.who.int/mediacentre/factsheets/fs369/fr."}, {"Citation": "Wittchen HU, M\u00fchlig S, Beesdo K. Mental disorders in primary care. Dialogues Clin Neurosci. 2003;5(2):115\u2013128.", "ArticleIdList": ["PMC3181625", "22034245"]}, {"Citation": "Demyttenaere K. Compliance during treatment with antidepressants. J Affect Disord. 1997;43(1):27\u201339.", "ArticleIdList": ["9127828"]}, {"Citation": "Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905\u20131917.", "ArticleIdList": ["17074942"]}, {"Citation": "Fournier JC, Derubeis RJ, Hollon SD, et al. Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA. 2010;303(1):47\u201353.", "ArticleIdList": ["PMC3712503", "20051569"]}, {"Citation": "Zimmermann TM, Clouth J, Elosge M, et al. Patient preferences for outcomes of depression treatment in Germany: a choice-based conjoint analysis study. J Affect Disord. 2013;148(2\u20133):210\u2013219.", "ArticleIdList": ["23290792"]}, {"Citation": "World Health Organization  Antidepressants (tricyclic antidepressants and selective serotonin reuptake inhibitors) in treatment of adults with depression. 2010.  [Accessed February 27, 2018].  Available from:  http://www.who.int/mental_health/mhgap/evidence/depression/mh_evidence_profile_q1_tca_ssri_2010_en.pdf."}, {"Citation": "Haute Autorit\u00e9 de Sant\u00e9  Episode d\u00e9pressif caract\u00e9ris\u00e9 de l\u2019adulte: prise en charge en soins de premier recours. 2017.  [Accessed March 27, 2018].  Available from:  https://www.has-sante.fr/portail/upload/docs/application/pdf/2017-10/depression_adulte_recommandations_version_mel.pdf."}, {"Citation": "National Institute for Health and Care Excellence . Depression in Adults: Recognition and Management. London: NICE; 2009.", "ArticleIdList": ["31990491"]}, {"Citation": "Mitchell J, Trangle M, Degnan B, et al.  Adult depression in primary care. 2013.  [Accessed March 27, 2018].  Available from:  http://pcptoolkit.beaconhealthoptions.com/wp-content/uploads/2016/02/ICSI_Depression.pdf."}, {"Citation": "Michigan Quality Improvement Consortium  Primary care diagnosis and management of adults with depression. 2018.  [Accessed March 1, 2018].  Available from:  http://www.mqic.org/pdf/mqic_primary_care_diagnosis_and_management_of_adults_with_depression_cpg.pdf."}, {"Citation": "Anthes E. Depression: a change of mind. Nature. 2014;515(7526):185\u2013187.", "ArticleIdList": ["25391944"]}, {"Citation": "Warrilow AE, Beech B. Self-help CBT for depression: opportunities for primary care mental health nurses? J Psychiatr Ment Health Nurs. 2009;16(9):792\u2013803.", "ArticleIdList": ["19824973"]}, {"Citation": "Noorbala AA, Akhondzadeh S, Tahmacebi-Pour N, Jamshidi AH. Hydro-alcoholic extract of Crocus sativus L. versus fluoxetine in the treatment of mild to moderate depression: a double-blind, randomized pilot trial. J Ethnopharmacol. 2005;97(2):281\u2013284.", "ArticleIdList": ["15707766"]}, {"Citation": "Moshiri E, Basti AA, Noorbala AA, Jamshidi AH, Abbasi SH, Akhondzadeh S. Crocus sativus L. (petal) in the treatment of mild-to-moderate depression: a double-blind, randomized and placebo-controlled trial. Phytomedicine. 2006;13(9\u201310):607\u2013611.", "ArticleIdList": ["16979327"]}, {"Citation": "Basti AA, Moshiri E, Noorbala AA, Jamshidi AH, Abbasi SH, Akhondzadeh S. Comparison of petal of Crocus sativus L. and fluoxetine in the treatment of depressed outpatients: a pilot double-blind randomized trial. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(2):439\u2013442.", "ArticleIdList": ["17174460"]}, {"Citation": "Hausenblas HA, Saha D, Dubyak PJ, Anton SD. Saffron (Crocus sativus L.) and major depressive disorder: a meta-analysis of randomized clinical trials. J Integr Med. 2013;11(6):377\u2013383.", "ArticleIdList": ["PMC4643654", "24299602"]}, {"Citation": "Mazidi M, Shemshian M, Mousavi SH, et al. A double-blind, randomized and placebo-controlled trial of saffron (Crocus sativus L.) in the treatment of anxiety and depression. J Complement Integr Med. 2016;13(2):195\u2013199.", "ArticleIdList": ["27101556"]}, {"Citation": "Shafiee M, Arekhi S, Omranzadeh A, Sahebkar A. Saffron in the treatment of depression, anxiety and other mental disorders: current evidence and potential mechanisms of action. J Affect Disord. 2018;227:330\u2013337.", "ArticleIdList": ["29136602"]}, {"Citation": "Akhondzadeh S, Fallah-Pour H, Afkham K, Jamshidi AH, Khalighi-Cigaroudi F. Comparison of Crocus sativus L. and imipramine in the treatment of mild to moderate depression: a pilot double-blind randomized trial [ISRCTN45683816] BMC Complement Altern Med. 2004;4:12.", "ArticleIdList": ["PMC517724", "15341662"]}, {"Citation": "Akhondzadeh S, Tahmacebi-Pour N, Noorbala AA, et al. Crocus sativus L. in the treatment of mild to moderate depression: a double-blind, randomized and placebo-controlled trial. Phytother Res. 2005;19(2):148\u2013151.", "ArticleIdList": ["15852492"]}, {"Citation": "Amsterdam JD, Panossian AG. Rhodiola rosea L. as a putative botanical antidepressant. Phytomedicine. 2016;23(7):770\u2013783.", "ArticleIdList": ["27013349"]}, {"Citation": "Yeung KS, Hernandez M, Mao JJ, Haviland I, Gubili J. Herbal medicine for depression and anxiety: a systematic review with assessment of potential psycho-oncologic relevance. Phytother Res. 2018;32(5):865\u2013891.", "ArticleIdList": ["PMC5938102", "29464801"]}, {"Citation": "Brichenko V, Kupriyanova I, Skorokhodova T. The use of herbal adaptogens together with tricyclic antidepressants in patients with psychogenic depressions. In: Goldberg ED, editor. Modern Problems of Pharmacology and Search for New Medicines. Tomsk: Tomsk University Press; 1986. pp. 58\u201360."}, {"Citation": "Brichenko V, Skorokhodova T. Herbal Adaptogens in Rehabilitation of Patients with Depression: Clinical and Organisational Aspects of Early Manifestations of Nervous and Mental Diseases. Vol. 15. Barnaul: Altajskoe Kni\u017ee; 1987."}, {"Citation": "Perfumi M, Mattioli L. Adaptogenic and central nervous system effects of single doses of 3% rosavin and 1% salidroside Rhodiola rosea L. extract in mice. Phytother Res. 2007;21(1):37\u201343.", "ArticleIdList": ["17072830"]}, {"Citation": "Darbinyan V, Aslanyan G, Amroyan E, Gabrielyan E, Malmstr\u00f6m C, Panossian A. Clinical trial of Rhodiola rosea L. extract SHR-5 in the treatment of mild to moderate depression. Nord J Psychiatry. 2007;61(5):343\u2013348.", "ArticleIdList": ["17990195"]}, {"Citation": "World Health Organization . International Statistical Classification of Diseases and Related Health Problems. 10th ed. Geneva: WHO; 2016. Mental and behavioural disorders; pp. F00\u2013F99."}, {"Citation": "Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23(1):56\u201362.", "ArticleIdList": ["PMC495331", "14399272"]}, {"Citation": "Maj M. Development and validation of the current concept of major depression. Psychopathology. 2012;45(3):135\u2013146.", "ArticleIdList": ["22399134"]}, {"Citation": "Mao JJ, Xie SX, Zee J, et al. Rhodiola rosea versus sertraline for major depressive disorder: a randomized placebo-controlled trial. Phytomedicine. 2015;22(3):394\u2013399.", "ArticleIdList": ["PMC4385215", "25837277"]}, {"Citation": "Cropley M, Banks AP, Boyle J. The effects of Rhodiola rosea L. extract on anxiety, stress, cognition and other mood symptoms. Phytother Res. 2015;29(12):1934\u20131939.", "ArticleIdList": ["26502953"]}, {"Citation": "Olsson EM, von Sch\u00e9ele B, Panossian AG. A randomised, double-blind, placebo-controlled, parallel-group study of the standardised extract SHR-5 of the roots of Rhodiola rosea in the treatment of subjects with stress-related fatigue. Planta Med. 2009;75(2):105\u2013112.", "ArticleIdList": ["19016404"]}, {"Citation": "Anghelescu IG, Edwards D, Seifritz E, Kasper S. Stress management and the role of Rhodiola rosea: a review. Int J Psychiatry Clin Pract. 2018 Jan 11; Epub.", "ArticleIdList": ["29325481"]}, {"Citation": "Basiri-Moghadam M, Hamzei A, Moslem AR, Pasban-Noghabi S, Ghorbani N, Ghenaati J. Comparison of the anxiolytic effects of saffron (Crocus sativus. L) and diazepam before herniorrhaphy surgery: a double blind randomized clinical trial. Zahedan J Res Med Sci. 2016;18(3):e6248."}, {"Citation": "Wu Z, Fang Y. Comorbidity of depressive and anxiety disorders: challenges in diagnosis and assessment. Shanghai Arch Psychiatry. 2014;26(4):227\u2013231.", "ArticleIdList": ["PMC4194005", "25317009"]}, {"Citation": "Lamers F, van Oppen P, Comijs HC, et al. Comorbidity patterns of anxiety and depressive disorders in a large cohort study: the Netherlands Study of Depression and Anxiety (NESDA) J Clin Psychiatry. 2011;72(3):341\u2013348.", "ArticleIdList": ["21294994"]}, {"Citation": "Fava M, Rush AJ, Alpert JE, et al. Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report. Am J Psychiatry. 2008;165(3):342\u2013351.", "ArticleIdList": ["18172020"]}, {"Citation": "Clayton PJ, Grove WM, Coryell W, Keller M, Hirschfeld R, Fawcett J. Follow-up and family study of anxious depression. Am J Psychiatry. 1991;148(11):1512\u20131517.", "ArticleIdList": ["1928465"]}, {"Citation": "Fava M, Uebelacker LA, Alpert JE, Nierenberg AA, Pava JA, Rosenbaum JF. Major depressive subtypes and treatment response. Biol Psychiatry. 1997;42(7):568\u2013576.", "ArticleIdList": ["9376453"]}, {"Citation": "Flint AJ, Rifat SL. Anxious depression in elderly patients: response to antidepressant treatment. Am J Geriatr Psychiatry. 1997;5(2):107\u2013115.", "ArticleIdList": ["9106374"]}, {"Citation": "Davidson JR, Meoni P, Haudiquet V, Cantillon M, Hackett D. Achieving remission with venlafaxine and fluoxetine in major depression: its relationship to anxiety symptoms. Depress Anxiety. 2002;16(1):4\u201313.", "ArticleIdList": ["12203668"]}, {"Citation": "Saveanu R, Etkin A, Duchemin AM, et al. The International Study to Predict Optimized Treatment in Depression (iSPOT-D): outcomes from the acute phase of antidepressant treatment. J Psychiatr Res. 2015;61:1\u201312.", "ArticleIdList": ["25586212"]}, {"Citation": "Tollefson GD, Holman SL, Sayler ME, Potvin JH. Fluoxetine, placebo, and tricyclic antidepressants in major depression with and without anxious features. J Clin Psychiatry. 1994;55(2):50\u201359.", "ArticleIdList": ["8077155"]}, {"Citation": "Russell JM, Koran LM, Rush J, et al. Effect of concurrent anxiety on response to sertraline and imipramine in patients with chronic depression. Depress Anxiety. 2001;13(1):18\u201327.", "ArticleIdList": ["11233456"]}, {"Citation": "Leucht S, Fennema H, Engel R, Kaspers-Janssen M, Lepping P, Szegedi A. What does the HAMD mean? J Affect Disord. 2013;148(2\u20133):243\u2013248.", "ArticleIdList": ["23357658"]}, {"Citation": "Forkmann T, Scherer A, Boecker M, Pawelzik M, Jostes R, Gauggel S. The Clinical Global Impression scale and the influence of patient or staff perspective on outcome. BMC Psychiatry. 2011;11:83.", "ArticleIdList": ["PMC3118175", "21569566"]}, {"Citation": "Gastpar M, Singer A, Zeller K. Comparative efficacy and safety of a once-daily dosage of Hypericum extract STW3-VI and citalopram in patients with moderate depression: a double-blind, randomised, multicentre, placebo-controlled study. Pharmacopsychiatry. 2006;39(2):66\u201375.", "ArticleIdList": ["16555167"]}, {"Citation": "Rampakakis E, Ste-Marie PA, Sampalis JS, Karellis A, Shir Y, Fitzcharles MA. Real-life assessment of the validity of patient global impression of change in fibromyalgia. RMD Open. 2015;1(1):e000146.", "ArticleIdList": ["PMC4623367", "26535150"]}, {"Citation": "Bystritsky A, Kerwin L, Feusner JD. A pilot study of Rhodiola rosea (Rhodax) for generalized anxiety disorder (GAD) J Altern Complement Med. 2008;14(2):175\u2013180.", "ArticleIdList": ["18307390"]}, {"Citation": "Lopresti AL, Drummond PD. Saffron (Crocus sativus) for depression: a systematic review of clinical studies and examination of underlying antidepressant mechanisms of action. Hum Psychopharmacol. 2014;29(6):517\u2013527.", "ArticleIdList": ["25384672"]}]}], "History": [{"Year": "2018", "Month": "7", "Day": "24", "Hour": "6", "Minute": "0"}, {"Year": "2018", "Month": "7", "Day": "24", "Hour": "6", "Minute": "0"}, {"Year": "2018", "Month": "7", "Day": "24", "Hour": "6", "Minute": "1"}, {"Year": "2018", "Month": "7", "Day": "13"}], "PublicationStatus": "epublish", "ArticleIdList": ["30034237", "PMC6049049", "10.2147/NDT.S169575", "ndt-14-1821"]}}]}